The study
The study OF·27 cites is a 12-week, single-blind, vehicle-controlled trichoscopy study of the active. It was conducted by Abich S.r.l., an accredited testing laboratory in Italy, under reference REL/0504/2026, in 40 women with diffuse thinning. It was commissioned and funded by Core Biogenesis, the developer of the active.
What was tested. The active, in a simple vehicle, against the same vehicle without the active.
How it was designed. Density was measured by trichoscopy (Note 08). Vehicle-controlled means the active was compared against an identical base without it. Single-blind means participants did not know which they were using. Measurements were taken at 4 timepoints over 84 days. 40 participants, split equally between active and vehicle.
What it found. At week 12, hair density in the active group was 33.5% above its own baseline (p < 0.0001). In the vehicle group it was 7.2% above baseline, which was not statistically significant. The study also reported at week 12: anagen-to-telogen ratio +17.0% (between groups, p = 0.0005), mean shaft diameter +10.6% (vs baseline, p = 0.0027), scalp hydration +22.2% (between groups, p < 0.0001) and transepidermal water loss −27.2% (vs baseline). No serious adverse events were reported.
Where it stops. 40 people is a defined sample, not a population. 12 weeks is the whole record; there is no data beyond it. The participants were women with diffuse thinning; men and other forms of hair loss were not studied. It was single-blind and single-centre, not a multi-centre trial. The figures are group averages; individual results ranged from no change to a large change.
Funding and publication. The study was funded by Core Biogenesis, the supplier of the active, and has been published in the International Journal of Clinical & Experimental Dermatology. The homepage FAQ links to it so you can weigh the funding against the data yourself. Note 10 describes the protocol the formula is used under.
Is there a clinical study on OF·27?
Not on the finished formula. OF·27 cites an independent twelve-week, single-blind, vehicle-controlled study of the oleosome-fusion FGF·2 active alone, in forty women with telogen effluvium, conducted by Abich S.r.l. (REL/0504/2026) and commissioned and funded by Core Biogenesis, the maker of the active.
How was the study designed?
Density was measured by phototrichogram; the active was compared against an identical vehicle without it; participants did not know which they received; measurements were taken at four timepoints over twelve weeks.
The notes, by email.
One note at a time, in reading order, and a message when a new one is published.
An independent hair-science program.
The protocol the notes describe: The OF·27 Protocol
OF·27 is marketed as a cosmetic and is not intended to diagnose, treat, cure or prevent any disease.